Agios Pharmaceuticals Inc. (AGIO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Agios Pharmaceuticals Inc... (AGIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

33.33

-0.97 (-2.83%)

At close: Jan 14, 2025, 3:59 PM

33.32

-0.03%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	30.88
Market Cap	1.90B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	11.62
PE Ratio (ttm)	2.87
Forward PE	n/a
Analyst	Buy

Ask	35.35
Volume	587,446
Avg. Volume (20D)	859,344
Open	34.61
Previous Close	34.30
Day's Range	32.85 - 34.98
52-Week Range	20.96 - 62.58
Beta	undefined

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 24, 2013

Employees 383

Stock Exchange NASDAQ

Ticker Symbol AGIO

Website https://www.agios.com

Analyst Forecast

According to 8 analyst ratings, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 62.02% from the latest price.

Buy 50.00%

Hold 37.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Agios Pharmaceuticals Inc. is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $11.10M, reflecting a 56.27% YoY growth and earnings per share of -1.77, making a 2.91% increase YoY.

Why Price Moved

2 months ago · Source

-4.04%

Agios Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

3 months ago · Source

-5.08%

Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.

News

6 days ago · zacks.com

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.

1 week ago · businesswire.com

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of car...

1 month ago · zacks.com

Here's Why Agios Stock Plummeted More Than 20% on Monday

The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.

1 month ago · zacks.com

4 Medical Product Stocks to Buy From a Prospective Industry

An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable fac...

1 month ago · zacks.com

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

2 months ago · zacks.com

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.

2 months ago · seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communicati...

2 months ago · zacks.com

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago.